SecBot SecBot

NUVB

Nuvation Bio Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001811063 Biotech & Drug Discovery
$4.61 +0.04 (+0.88%)
Oct 26 4:00 PM ET · prev $4.57
Market cap
$1.7B
Small cap
Consensus
Buy
89% Buy or better · 19 analysts
Median target
$12.00
+160% · range $7.00–21.00
Next earnings
Nov 4
in 9 days
1 year
−8.5%
from $5.04 · Oct 27
30 days
−17.7%
from $5.60
52-week range
$4.05–9.54
−52% from high · low Mar 30
Avg volume 20D
5.49M
Oct 2 spike 14.82M
Short interest
58.86M
≈16.8% of shares · +1.2%
Days to cover
13.9
at average volume
Insider net
-$3.3M
1 buyer · 5 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 4, 2026
Strongest MIXED Nuvation Bio reported Q2 2026 total revenue of $31.7M, including $23.2M in IBTROZI product revenue (25% QoQ…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $118.3K at an average $4.73. 5 insiders sold $3.5M.

  • InstitutionsBULLISH

    Q2 2026: 35 added (1 new), 13 trimmed or exited. Largest new: Hrt Financial $12.5M.

  • AnalystsBULLISH

    17 of 19 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +1.2% to 58.86M shares. 13.9 days to cover, ≈16.8% of shares.

  • TrendDOWNTREND

    21% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$12.5M
in new stakes
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD4,499,643$25.6M
HRT FINANCIAL LPNEW2,207,779$12.5M
Connor, Clark & Lunn Investment Management Ltd.ADD1,756,820$10.0M
Jump Financial, LLCDOUBLED1,358,411$7.7M
RENAISSANCE TECHNOLOGIES LLCDOUBLED1,345,995$7.6M
D. E. Shaw & Co., Inc.DOUBLED1,140,000$6.5M
Nuveen, LLCDOUBLED1,083,628$6.2M
SILVERCREST ASSET MANAGEMENT GROUP LLCADD1,021,526$5.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 89% rate it Buy or better
Strong Buy5Buy12Hold2Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +160%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 30, 2026Citigroup
INITIATE
INITIATEBuy
Sep 16, 2026Citizens
REITERATE
REITERATEMarket Outperform
Sep 16, 2026Wedbush
REITERATE
REITERATEOutperform
Aug 21, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Aug 18, 2026JP Morgan
INITIATE
INITIATEOverweight
Aug 7, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$118.3K
bought · 1 insider
$3.5M
sold · 5 insiders
−2.5%
vs their $4.73 cost
DateInsiderTypeValue
Aug 19, 2026
Hattersley Gary
CHIEF SCIENTIFIC OFFICER
EXERCISE$187.0K
Aug 19, 2026
Hattersley Gary
CHIEF SCIENTIFIC OFFICER
SELL$709.2K
Jul 15, 2026
Sauvage Philippe
Chief Financial Officer
EXERCISE$86.8K
Jul 15, 2026
Sauvage Philippe
Chief Financial Officer
EXERCISE$1.97
Jun 23, 2026
Sauvage Philippe
Chief Financial Officer
EXERCISE$103.4K
Jun 23, 2026
Wentworth Kerry
CHIEF REGULATORY OFFICER
EXERCISE$184.6K
Jun 23, 2026
Wentworth Kerry
CHIEF REGULATORY OFFICER
SELL$379.2K
Jun 23, 2026
Markel Stacy
CHIEF PEOPLE OFFICER
EXERCISE$169.0K

Earnings setup

Estimates
Nov 4
reports in 9 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
58,862,812
shares short
+1.2%
vs prior settlement
13.9
days to cover
≈16.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Nuvation Bio, Inc. announced it will report its Q3 2026 results on November 4, 2026.
PRESS-RELEASE — Impact 1/10
Oct 21, 2026 Earnings
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global on
Sep 16, 2026 Event
IBTROZI
Supplemental Approval — Efficacy — TALETRECTINIB — CAPSULE — ORAL
Aug 19, 2026 Insider
Hattersley Gary acquired via exercise 100,000 shares
CHIEF SCIENTIFIC OFFICER @ $1.87 ($187.0K)
Aug 19, 2026 Insider
Hattersley Gary sold 100,000 shares
CHIEF SCIENTIFIC OFFICER @ $7.09 ($709.2K)
Aug 6, 2026 SEC
Nuvation Bio reported Q2 2026 total revenue of $31.7M, including $23.2M in IBTROZI product revenue (25% QoQ growth)…
8-K — Impact 5/10
Jul 15, 2026 Insider
Sauvage Philippe acquired via exercise 39,999 shares
Chief Financial Officer @ $2.17 ($86.8K)
Jun 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC — ADD
4,499,643 shares ($25.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
NUVB Q3 2026 Earnings Scheduled — 2026-11-04
Jan 4, 2027
FDA decision date
PDUFA: NUVB — IBTROZI in advanced ROS1-positive non-small cell lung cancer — 2027-01-04
FDA target action date 2027-01-04 for NUVB (Nuvation Bio Inc.). Drug: IBTROZI. Indication: advanced ROS1-positive non-small cell lung cancer. FDA…
Recent
Oct 21, 2026
Earnings
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the…
Sep 16, 2026
FDA
IBTROZI
Supplemental Approval — Efficacy — TALETRECTINIB — CAPSULE — ORAL
Sep 2, 2026
Press release
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest…
Aug 6, 2026
Earnings date
NUVB Q2 2026 Earnings Scheduled — 2026-08-06
Jul 6, 2026
Press release
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
NEW YORK, July 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the…

SecBot reports

8 filings · 0 bullish · 2 bearish · 2 mixed · 4 neutral
All NUVB filing & press-release reports (8)